Cover Image

歐盟5國的MA (醫療事務) 部門的評估:腎細胞癌

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2017

出版商 FirstWord 商品編碼 497073
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
歐盟5國的MA (醫療事務) 部門的評估:腎細胞癌 Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2017
出版日期: 2017年04月01日 內容資訊: 英文

本報告依據處理腎細胞癌治療藥的主要9項產品的各公司醫療事務 (MA) 團隊的150名歐盟5國 (法國、義大利、德國、西班牙、英國)的腫瘤專門醫生的調查結果,各公司隊的效能及滿意度的評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析彙整。


  • Afinitor (Everolimus:Novartis)
  • Avastin (Bevacizumab:Roche)
  • Cabometyx (Cabozantinib:Exelixis/Ipsen)
  • Inlyta (Axitinib :Pfizer)
  • Nexavar (Sorafenib:Bayer)
  • Opdivo (Nivolumab:Bristol-Myers Squibb)
  • Sutent (Sunitinib:Pfizer)
  • Torisel (Temsirolimus:Pfizer)
  • Votrient (Pazopanib:Novartis)


  • 醫生的需求
    • 醫生的MA團隊的利用方法、頻率
    • 最考慮重要的服務
    • 最適合的聯繫頻率和途徑
  • MA團隊提供的內容
    • 醫生跟團隊的互動的印象
    • 醫生的團隊效能、滿意度排行榜:12項
    • 與其他團隊的比較
  • 改善需要的地方等

Better information provision could give your medical affairs team a boost with doctors

Is your medical affairs team giving doctors the information they need? Maybe not, according to our survey of 100 medical oncologists. As part of list of suggested improvements, they identified at least 4 ways that teams for major renal cell carcinoma (RCC) treatments could do a better job of providing information. Could taking their suggestions help your team close the gap with the runaway market leader?

Find out, and learn what else you can do to boost your team's performance and satisfaction scores in Medical Affairs Reputations: RCC (EU5).

Comparing 9 major RCC treatments from Bayer, Bristol-Myers Squibb, Exelixis, Ipsen, Novartis, Pfizer, and Roche, this report reveals:

  • How oncologists rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important.
  • How, and how often oncologists want to meet with your team.
  • What you can do to improve your medical affairs services.

That's actionable information you can use to turn your team into one that doctors rely on.

Request sample pages

Top Takeaways

  • Teams are doing an adequate job, but could be doing better: Across the board, scores for both performance and satisfaction are hovering just above neutral.
  • Doctors have plenty of suggestions: They pointed to at least 5 different ways teams can improve information provision. They're also calling for a better medical-affairs “attitude.”
  • One team is way ahead: Rated for overall quality of interactions, the top team scores more than twice as high as its closest rival. It also outperforms on nearly every medical affairs service.
  • Most teams need to improve specific services: six of the nine surveyed teams need to improve at least one of the medical affairs services covered in the report.
  • Doctors want frequent, face-to-face meetings: Doctors prefer in-person interactions to other methods. They also prefer to be contacted more often than most teams are reaching out.
  • Actionable information is the top priority: Four of the five most important roles for medical affairs teams involve providing information doctors can use to make better treatment decisions.

Insight into Medical Affairs Teams for These RCC Treatments

  • Afinitor (everolimus; Novartis)
  • Avastin (bevacizumab; Roche)
  • Cabometyx (cabozantinib; Exelixis/Ipsen)
  • Inlyta (axitinib; Pfizer)
  • Nexavar (sorafenib; Bayer)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Sutent (sunitinib; Pfizer)
  • Torisel (temsirolimus; Pfizer)
  • Votrient (pazopanib; Novartis)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 9 medical affairs teams-answering important questions like:

What do doctors need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 medical oncologists from the EU5 (France, Italy, Germany, Spain, UK) -chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with RCC in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the past 6 months.

We conducted the survey between March 2nd and 8th, 2017.

Back to Top